Latest News

Sales rep restrictions point to need for a pharma rethink

Sales rep restrictions point to need for a pharma rethink

A survey shows sales rep bans are accelerating, while also pointing to a limited-time opportunity for pharma to become a significant partner for healthcare systems.

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Five things for pharma marketers to know: Wednesday, October 1

Five things for pharma marketers to know: Wednesday, October 1

Ebola lands in the US; CMS's Open Payments database shows docs received $3.5 billion in last five months of 2013; Endo pays over $400 million to settle vaginal mesh suits.

Sucampo goes all-in on Amitiza with new DTC effort

Sucampo goes all-in on Amitiza with new DTC effort

The drugmaker is debuting a DTC campaign for the older constipation drug, despite a crowded therapeutic category and potential generics on the horizon.

Payers OK-ish with orphan drug prices

A survey shows fewer payers expect more restrictive policies in the near-term.

American Academy of Neurology releases opioid policy

The reveal comes days before hydrocodone products jump to a more restrictive access tier.

Five things for pharma marketers to know: Tuesday, September 30

Five things for pharma marketers to know: Tuesday, September 30

New Pfizer Viagra ads bring women into limelight; Open Payments database debuts to criticism; AbbVie/Shire deal set to be completed.

BMS cancer agent stacks up against Merck's, but AZ's IO steals show

BMS cancer agent stacks up against Merck's, but AZ's IO steals show

Late-stage immunotherapy results presented at a European medical conference over the weekend were heralded by clinicians, as AstraZeneca's lung-cancer darkhorse showcased strong early-stage results.

Pacira gets OPDP opioid promotion Warning Letter

Pacira gets OPDP opioid promotion Warning Letter

The FDA's Office of Prescription Drug Promotion says Pacira's promotional materials for Exparel are "extremely concerning," but the drugmaker tells investors the fuss is probably because opioids have been getting a lot of attention lately.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.